Form 4: Bioventus Director Guy Nohra Executes RSU Transactions

Director Guy Nohra acquired 32,282 shares of Bioventus Class A Common Stock through RSU vesting and was granted 25,146 new RSUs.

Summary

• Director Guy P. Nohra exercised 32,282 Restricted Stock Units (RSUs) on June 2, 2026, which vested and converted into Class A Common Stock.
• Following the transaction, the director holds 148,892 shares of Class A Common Stock.
• On June 3, 2026, the director was granted an additional 25,146 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard director compensation and does not indicate a change in the company's fundamental outlook or strategic direction.

Positives

• Director maintains a significant equity stake of 148,892 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Future vesting of the 25,146 newly granted RSUs is contingent upon the director continuing service on the Board of Directors.

Future Outlook

The newly granted 25,146 RSUs are scheduled to vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date, provided the director remains in service.

Industry Context

StockSavvy.ai notes that this filing represents routine equity-based compensation for corporate directors, which is standard practice in the medical device and biotechnology sectors to ensure long-term board commitment.

Comparison to Industry Standards

• The use of RSUs as a primary component of director compensation is consistent with standard corporate governance practices for mid-cap healthcare companies.
• The vesting schedule aligns with typical annual equity grant cycles observed in the industry.

Stakeholder Impact

• Shareholders may view the director's continued equity retention as a sign of confidence in the company's long-term prospects.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership